A tumour vaccine of fixed tumour fragments in a controlled-release vehicle with cytokines for therapy of hepatoma in mice

作者：Kushida, S; Peng, BG; Uchimura, E; Kuang, M; Huang, L; Miwa, M; Ohno, T^*

来源：Digestive and Liver Disease, 2004, 36(7): 478-485.

DOI：10.1016/j.dld.2004.02.010

• cytokine-vehicle
• hepatoma
• tumour vaccine

Background. Cytokines can be strong potentiators for a tumour vaccine, but they have very short life in vivo when administered as a solution.
Aims. To evaluate the slow release of interleukin 2 from a cytokine-vehicle in vitro and in vivo and to evaluate the anti-tumour activity of a new tumour vaccine in vivo.
Methods. The tumour vaccine was composed of formalin-fixed Hepa 1-6 hepatoma tissue fragments, tuberculin and a lipid based vehicle containing granulocyte-macrophage colony-stimulating factor and interleukin 2. The quantity of interleukin 2 release from the cytokine-vehicle in vitro and in vivo was determined by a proliferation assay with CTLL-2 cell line. Hepa 1-6 hepatoma model system with C57BL/6J mice was used to examine protective and therapeutic anti-tumour effect of the vaccine.
Results. Release of interleukin 2 from the cytokine-vehicle lasted 5 days in vitro and 3 days in vivo. The vaccine protected 67% of mice from a Hepa 1-6 cell challenge and had a therapeutic effect by prolonging the life span of mice bearing established Hepa 1-6 tumours of 5 rum in diameter. Of the treated mice, 20% became completely tumour-free.
Conclusions. Formalin-fixed tumour fragments and cytokines in controlled-release vehicle are useful in the rational design of tumour vaccines.

• 出版日期2004-7
• 单位中山大学